Distinguished in Gigantism

Dr. Maria Fleseriu

Endocrinology
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
Offers Telehealth
Distinguished in Gigantism
University Professional Services
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maria Fleseriu is an Endocrinologist in Portland, Oregon. Dr. Fleseriu is rated as a Distinguished provider by MediFind in the treatment of Gigantism. Her top areas of expertise are Acromegaly, Cushing's disease, Cushing's syndrome, Acromegaloid Facial Appearance Syndrome, and Hormone Replacement Therapy (HRT).

Her clinical research consists of co-authoring 247 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in OR
Hospital Affiliations
Ohsu Hospital And Clinics
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AllCare Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
OHSU Health
  • MANAGED MEDICAID PLAN
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UNIVERSITY PROFESSIONAL SERVICES
3181 Sw Sam Jackson Park Rd, Portland, OR 97239

Additional Areas of Focus

Dr. Fleseriu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

247 Total Publications

Osilodrostat-associated Adrenal Gland Shrinkage: a Case Series of Patients with ACTH-Dependent Cushing's Syndrome.
Osilodrostat-associated Adrenal Gland Shrinkage: a Case Series of Patients with ACTH-Dependent Cushing's Syndrome.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 17, 2025
Similar Doctors
Advanced in Gigantism
Dr. Elena Varlamov
Endocrinology
Advanced in Gigantism
Dr. Elena Varlamov
Endocrinology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (0.1 miles away)
503-494-8311
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Varlamov is an Endocrinologist in Portland, Oregon. Dr. Varlamov has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Gigantism. Her top areas of expertise are Pituitary Tumor, Prolactinoma, Hypothalamic Tumor, and Acromegaly.

Advanced in Gigantism
Dr. Katherine Chubinskaya
Endocrinology
Advanced in Gigantism
Dr. Katherine Chubinskaya
Endocrinology

Peacehealth

400 Ne Mother Joseph Pl, 
Vancouver, WA 
 (10.1 miles away)
360-514-1734
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Katherine Chubinskaya is an Endocrinologist in Vancouver, Washington. Dr. Chubinskaya is rated as an Advanced provider by MediFind in the treatment of Gigantism. Her top areas of expertise are Pediatric Growth Hormone Deficiency, Sheehan Syndrome, Panhypopituitarism, and Hypogonadism.

Experienced in Gigantism
Dr. Sarah C. Soltman
Endocrinology
Experienced in Gigantism
Dr. Sarah C. Soltman
Endocrinology
4805 Ne Glisan St Ste 6n40, 
Portland, OR 
 (5.0 miles away)
503-215-6601
Languages Spoken:
English
See accepted insurances

Sarah Soltman is an Endocrinologist in Portland, Oregon. Dr. Soltman is rated as an Experienced provider by MediFind in the treatment of Gigantism. Her top areas of expertise are Acromegaly, Gigantism, Sotos Syndrome, and Thyroid Storm.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fleseriu's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 8 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile